Actively Recruiting
Thoracic Surgery Intercostal Block Trial With Liposomal vs. Hydrochloride Bupivacaine
Led by Shanghai Pulmonary Hospital, Shanghai, China · Updated on 2026-03-30
210
Participants Needed
1
Research Sites
54 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This randomized controlled trial evaluates the analgesic effects of liposomal bupivacaine compared to bupivacaine hydrochloride in intercostal nerve block for patients undergoing thoracoscopic lung surgery. Postoperative pain remains a significant issue in thoracic procedures, often leading to complications like pneumonia or delayed recovery. The investigators hypothesize that liposomal bupivacaine, with its extended-release properties, will provide superior pain relief beyond 24 hours compared to standard bupivacaine or no block. Participants will be randomized 1:1:1 to liposomal bupivacaine group , bupivacaine hydrochloride group , or control group . Primary outcome is the area under the curve of pain scores from 25-72 hours post-surgery. Secondary outcomes include opioid consumption, recovery quality (QoR-15), and other complications.
CONDITIONS
Official Title
Thoracic Surgery Intercostal Block Trial With Liposomal vs. Hydrochloride Bupivacaine
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Scheduled for elective unilateral thoracoscopic (VATS) lung surgery
- Age 18 to 80 years
- American Society of Anesthesiologists (ASA) physical status I-III
You will not qualify if you...
- Contraindication to local anesthetics such as infection at puncture site, allergy, coagulopathy, or bleeding risk
- Sensory abnormalities in the planned chest-wall surgical area
- Hepatic dysfunction with ALT > 50 U/L, AST > 40 U/L, or total bilirubin ≥ 19 µmol/L
- Renal dysfunction with serum creatinine > 112 µmol/L, BUN > 7.1 mmol/L, or dialysis within 28 days before surgery
- Pregnancy, breastfeeding, women of childbearing potential not using adequate contraception, or planning pregnancy during study
- Preoperative opioid use, history of chronic pain, or opioid abuse
- Refusal to provide informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai pulmonary hospital
Shanghai, China
Actively Recruiting
Research Team
S
Shiyou Wei, PhD
CONTACT
X
Xin Lv, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here